Rapid point-of-care molecular test for HCV VL

摘要 丙型肝炎，一种由丙型肝炎病毒(丙型肝炎病毒)引起的炎症性肝病，声称约有40万人 每年死于继发性肝细胞癌和肝硬变所致的肝功能衰竭。直接演戏 抗病毒药物可以治愈全球约7100万丙型肝炎病例中的95%，但由于 在诊断不足的情况下，目前只有7%的患者正在接受治疗。丙型肝炎病毒的诊断检测算法 需要多次去诊所就诊。弱势群体中的个人往往缺乏达到这种高水平的手段 后续负担。增加丙型肝炎病毒治疗的流行率以反映95%的治愈率需要简化 诊断性测试。为此，我们将开发一种样本到答案的丙型肝炎病毒载量(VL)测试，以满足或 超过丙型肝炎全球利益相关者联盟定义的最低可接受标准。 为了实现这一目标，我们将把Redbud Labs在微流体和系统方面的专业知识与诊断 PATH(西雅图，华盛顿州)诊断计划的测试开发专业知识。在AIM 1中，Redbud实验室将 使用Redbud技术将每个分析步骤优化到微流控环境，并将其商业化 可用的试剂。在Aim 2中，Path将设计检测引物和探针。在AIM 3中，Redbud实验室将验证 通过使用面包板系统进行端到端的检测。紫百合的技术已经可以投入生产了， 这将最大限度地减少我们在进行试剂盒集成时检测性能下降的风险 未来二期工作。

ABSTRACT Hepatitis C, the inflammatory liver disease caused by hepatitis C virus (HCV), claims approximately 400,000 lives each year from secondary hepatocellular carcinoma and cirrhosis-induced liver failure. Direct-acting antiviral agents can cure > 95% of the estimated 71 million cases of hepatitis C found globally, yet because of underdiagnosis, only 7% of patients are currently receiving treatment. The diagnostic testing algorithm for HCV necessitates multiple clinic visits. Individuals in vulnerable populations often lack the means to meet this high follow-up burden. Increasing the prevalence of HCV treatment to reflect the 95% cure rate requires simplification of diagnostic testing. To this end we will develop a sample-to-answer HCV viral load (VL) test that meets or exceeds the minimal acceptable criteria as defined by the hepatitis C global stakeholder consortium. To achieve this goal, we will combine Redbud Labs’ expertise in microfluidics and systems with the diagnostic assay development expertise of the Diagnostics Program at PATH (Seattle, WA). In Aim 1 Redbud Labs will optimize each assay step to the microfluidic environment using Redbud technologies and commercially available reagents. In Aim 2 PATH will design assay primers and probes. In Aim 3 Redbud Labs will validate the assay by performing it end-to-end using a breadboard system. Redbud technologies are production-ready, which will minimize the risk of degradation in assay performance as we move through cartridge integration in future Phase II work.